查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球输血诊断市场
市场调查报告书
商品编码
1153814

2022-2029 年全球输血诊断市场

Global Transfusion Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

输血诊断市场预计2021年将达到39.5529亿美元，2029年将达到67.0735亿美元，在预测期内（2022-2029年）以9.68%的复合年增长率增长。

输血是将血液输送到体内。输血用于各种医疗条件，以替代丢失的血液成分。输血可替代手术期间或因严重受伤而流失的血液。当身体因血癌等疾病而无法正常生产血液时，也可以使用输血。

市场动态

血癌、重伤和事故的发病率不断增加，增加了对这些诊断的需求。手术数量的增加、研发支出的增加以及新产品发布的增加预计将推动市场增长。

新产品发布的增加、严重伤害和事故案例的增加是市场增长的驱动力。

由于血癌、贫血、镰状细胞性贫血、肾病等慢性病和输血感染等严重感染的增加，医疗行业对诊断的需求推动了全球输血诊断市场的发展.被拖走。越来越多的事故和伤害以及痛苦的手术将推动市场增长。例如，2022 年 8 月，QuidelOrtho Corporation 宣布其子公司体外诊断服务提供商 Ortho Clinical 开发的 Ortho 工作站获得了 AABB“符合标准”指定质量印章。该工作站是集培养箱和离心机于一体的二合一血液检测系统。

各种资金来源、新技术进步以及越来越多的最新创新产品发布导致对这些输血诊断的高需求。例如，2022 年 7 月，罗氏推出了 Elecsys HCV Duo 免疫分析，这是第一个能够从单个人体样本中独立检测丙型肝炎病毒抗体和抗原状态的免疫分析。该测试可以及早发现感染，可用于正在康復或出现慢性感染症状的患者。

与输血诊断相关的高成本阻碍了市场增长。

然而，用于输血诊断的有质量保证的试剂盒和仪器的高成本是限制增长的主要因素。缺乏经验丰富的专业人员使得很难使用自动化设备并提供准确的结果。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了负面影响。 COVID-19 的爆发严重影响了医疗保健行业。由于所有献血都停止，输血诊断市场因 COVID 遭受了巨大损失。由于 COVID 和输血感染的传播，人们拒绝输血。但现在，市场进入者正在改变他们的长期和短期增长战略，利用研究市场和创造尖端项目来对抗这一流行病。世界各地正在发生各种举措、合作和合併，推动了市场的增长。例如，2022 年 8 月，体外诊断创新技术提供商 QuidelOrtho Corp 宣布加入联盟，该联盟是血液和生物治疗促进协会成立的联盟，旨在加强血液供应。

内容

第 1 章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第四章市场动态

  • 市场影响因素
    • 司机
      • 新产品发布次数增加
      • 对输血诊断试剂的需求增加
    • 约束因素
      • 与输血诊断设备相关的高成本
    • 机会
    • 影响分析

第五章行业分析

  • 搬运工的五种力量
  • 未满足的需求
  • 供应链分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按产品类型

  • 设备/套件
  • 试剂
  • 其他

第8章按输血类型

  • 红细胞输注
  • 血小板输注
  • 血浆输注
  • 全血输血

第 9 章按应用

  • 疾病筛查
  • 血型测试
  • 其他

第 10 章最终用户

  • 血库
  • 医院
  • 实验室
  • 血浆分离设施
  • 其他

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第13章公司简介

  • Ortho Clinical Diagnostics
    • 公司简介
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Beckman Coulter
  • Quotient Limited
  • Abbott Laboratories
  • Diagast
  • Becton, Dickinson & Company
  • Immucor Inc.
  • Grifols S.A.
  • Bio-Rad Laboratories
  • F. Hoffmann-La Roche Ltd.

第14章 全球输血诊断市场-DataM

简介目录
Product Code: DMMDP858

Market Overview

Transfusion Diagnostics Market was valued at US$ 3,955.29 million in 2021 and is estimated to reach US$ 6,707.35 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).

Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost blood components. Blood transfusions replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can't make blood properly because of an illness such as blood cancer.

Market Dynamics

The increasing demand for these diagnostic products is due to the rising incidence of blood cancer, serious injuries, and accidents. The rising number of surgeries, increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and rising number of serious injuries and accident cases will drive market growth.

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market's growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB "standards compliant" designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient's recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market's growth.

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Segment Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection.

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria.

Geographical Analysis

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world's population.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada's national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Competitive Landscape

The transfusion diagnostics market is highly competitive with local and global companies' presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States.

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing demand for diagnostic transfusion products
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with diagnostic transfusion instruments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Instruments & Kits*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Reagents
  • 7.4. Others

8. By Transfusion Types

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 8.1.2. Market Attractiveness Index, By Transfusion Types
  • 8.2. Red Blood Cell Transfusion *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Platelet Transfusion
  • 8.4. Plasma Transfusion
  • 8.5. Whole Blood Transfusion

9. By Application

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.1.2. Market Attractiveness Index, By Application
  • 9.2. Disease Screening *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Blood Typing
  • 9.4. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Blood Banks*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Hospitals
  • 10.4. Laboratories
  • 10.5. Plasma Fractionation Facilities
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Transfusion Types
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), End-User
    • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. Ortho Clinical Diagnostics
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Beckman Coulter
  • 13.3. Quotient Limited
  • 13.4. Abbott Laboratories
  • 13.5. Diagast
  • 13.6. Becton, Dickinson & Company
  • 13.7. Immucor Inc.
  • 13.8. Grifols S.A.
  • 13.9. Bio-Rad Laboratories
  • 13.10. F. Hoffmann-La Roche Ltd.

LIST NOT EXHAUSTIVE

14. Global Transfusion Diagnostics Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us